Built on substance, not hype, Teva's mega rally is just getting started.
A group of senators are pressing the US Food and Drug Administration (FDA) to provide a more predictable pathway to market for generic opioid painkillers in the hopes of ensuring that new versions of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results